EINPresswire/ -- Faex Health, a fast-growing digital health startup, today announced the release of its C. difficile (C. diff) detection feature, making it one of the first AI platforms to screen for ...

Recurring Clostridioides difficile infections could be costing hospitals millions, an AtlantiCare Regional Medical Center study found. The study, published Sept. 29 in Cambridge Core, included 29 ...

As the effectiveness of antibiotics meant to fight the deadly superbug Clostridioides difficile, or C. diff, wanes, a research team at the University of Houston is seeing positive results of a new ...

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Clostridioides difficile (C. diff) is a stealthy threat. It infects more than 500,000 people in the United States each year, and kills up to 30,000. It is a ...

C. diff, which is short for Clostridioides difficile, is a type of bacteria that may cause serious problems in the digestive system. It is one of the most common causes of diarrhea linked to ...

The bacterium Clostridium difficile — otherwise known as C. diff — spreads within intensive care units more than three times as much as previously thought, according to a study published on April 4 in ...

The pathogen C. diff -- the most common cause of health care-associated infectious diarrhea -- can use a compound that kills the human gut's resident microbes to survive and grow, giving it a ...

Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2.

Please provide your email address to receive an email when new articles are posted on . More patients in the bezlotoxumab group experienced recurrence vs. the placebo group (13% vs. 3%). Steroid use ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a ...

St. Louis-based Washington University School of Medicine researchers found that fidaxomicin, a treatment for Clostridioides difficile infection, has increased in use but “remains underutilized.” The ...